Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Moodys
Medtronic
McKinsey
Mallinckrodt

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,435,752

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,435,752
Title:Gene polymorphisms predictive for dual TKI therapy
Abstract: The invention provides compositions and methods for determining the likelihood of successful treatment with dual therapy such as lapatinib. The methods comprise determining the genomic polymorphism or expression level of a gene present in a predetermined region of a gene of interest and correlating the polymorphism or expression level to the predictive response. Patients identified as likely responsive are then treated with the appropriate therapy.
Inventor(s): Lenz; Heinz-Josef (Los Angeles, CA)
Assignee: University of Southern California (Los Angeles, CA)
Application Number:12/523,514
Patent Claims:1. A method for treating a human cancer patient suffering from gastric cancer, comprising administering an effective amount of lapatinib to a gastric cancer patient selected for said therapy based on possession of a genetic marker A/A for IL-8 T251A SNP, thereby treating said patient.

2. The method of claim 1, wherein the patient is suffering from advanced or metastatic gastric cancer.

3. The method of claim 1, further comprising administering an effective amount of a therapy selected from trastuzumab, capecitabine, letrozole, paclitaxel and FOLFIRI (irinotecan, 5-fluorouracil and leucovorin).

4. The method of claim 1, wherein the (A/A) for IL-8 T251A SNP is determined by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) of a tissue sample isolated from the patient.

5. The method of claim 1, wherein gene expression of IL-8 is determined by Reverse Transcriptase-Polymorphism Cain Reaction (RT-PCR).

6. The method of claim 1, wherein the patient is selected for the therapy aided by the determination that the patient is more likely responsive to the therapy than a patient lacking possession of the A/A for IL-8 T251A SNP genetic marker or more likely to experience longer overall survival than a patient lacking possession of the A/A for IL-8 T251A SNP genetic marker.

Summary for Patent:   Start Trial

PCT Information
PCT FiledJanuary 17, 2008PCT Application Number:PCT/US2008/000661
PCT Publication Date:July 24, 2008PCT Publication Number:WO2008/088861

Details for Patent 8,435,752

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial University of Southern California (Los Angeles, CA) 2027-01-18 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Dow
AstraZeneca
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.